OncoMatch/Clinical Trials/NCT06427330
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Is NCT06427330 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Inotuzumab ozogamicin for acute lymphoid leukemia.
Treatment: Inotuzumab ozogamicin — To learn about the safety of post-HSCT two dose Inotuzumab Ozogamicin to participants with high risk B cell acute lymphoblastic leukemia(B-ALL). Also, to learn if giving Inotuzumab Ozogamicin to post-HSCT patients with high-risk B- ALL can help to reduce relapse and prolong disease free survival and overall survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD22 overexpression (positive)
Diagnosis of CD22-positive Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: hematopoietic stem cell transplant — allogeneic or autologous
Patients who underwent an allogeneic hematopoietic stem cell transplantation(HSCT) from any donor source or auto-HSCT for acute lymphocytic leukemia
Lab requirements
Blood counts
ANC > 1,000/µL for 3 days and platelet transfusion independence as defined as a platelet count > 50,000/µL for 7 days
Kidney function
Severe renal deficiency, with creatinine clearance < 50ml/min
Liver function
Severe hepatic deficiency; Bilirubin, AST, and/or ALT > 2X institutional upper limit of normal
Cardiac function
Severe cardiac deficiency
Participants must have ANC > 1,000/µL for 3 days and platelet transfusion independence as defined as a platelet count > 50,000/µL for 7 days. Severe renal deficiency, with creatinine clearance < 50ml/min. Severe hepatic deficiency. Bilirubin, aspartate aminotransferase(AST), and/or ALT(ALT) > 2X institutional upper limit of normal. Severe cardiac or pulmonary deficiency.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06427330 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received hematopoietic stem cell transplant.
Does this trial require CD22?
Yes, CD22 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages